Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients

Next Previous
Trial Profile

A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Sep 2022 Results of preliminary analysis assessing the efficacy and safety of anlotinib combined with toripalimab in the first-line treatment of patients with unresectable or metastatic UPS presented at the 47th European Society for Medical Oncology Congress
  • 08 Jul 2019 Planned End Date changed from 19 Jun 2023 to 19 Jul 2023.
  • 08 Jul 2019 Planned primary completion date changed from 19 Jun 2022 to 19 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top